Elevance Health Inc.

Our stress test evaluates an adverse 12-to-24 month underwriting stagflation scenario where medical loss ratios remain elevated above 91.0%, Medicaid redetermination rate catch-ups lag into fiscal 2027, and commercial group medical cost inflation stays in the low double digits. In this scenario, consolidated operating margin remains suppressed below 2.5%, preventing normalization toward the 4.2% house target. The compounding effect of historical CMS risk adjustment data liabilities ($935M pre-tax charge in 9M 2026) and membership attrition to national peers UNH and CI would compress operating earnings growth to 3%-5%, testing debt service coverage and constraining share repurchase capacity.

Narrow

Elevance Health possesses a Narrow economic moat grounded in structural cost advantages from local market scale, exclusive Blue Cross Blue Shield (BCBS) brand licensing in 14 states, and expanding fee-based healthcare services via Carelon. In managed care, scale is fundamentally local: health plans with dominant regional market share negotiate superior unit-cost discounts with hospitals and physician networks, directly lowering the underlying cost of care and creating a durable pricing advantage over smaller competitors.

In addition to scale-based provider cost advantages, Elevance benefits from meaningful switching costs in its Commercial Fee-Based (27.6M members) and Employer Group books. Replacing an established managed care administrator disrupts employee doctor relationships, requires extensive IT and benefits re-enrollment, and exposes corporate sponsors to network friction. The return of several jumbo accounts to Anthem after a single year with a competitor highlights the operational moat protecting Elevance's employer franchise.

The rapid development of Carelon (CarelonRx and Carelon Services) strengthens the moat by integrating clinical, behavioral, and pharmacy services into risk-bearing and administrative plans. Carelon delivered $19.3B in operating revenue and $0.9B in operating gain in Q3 2026 (up 17% YoY), achieving a 5.3% margin in CarelonRx. This vertical integration retains profit internally, reduces medical cost trend, and captures external selling opportunities with third-party payers.

The moat remains Narrow rather than Wide due to substantial regulatory dependence and customer concentration in government programs. With 8.2M Medicaid members and 2.8M Medicare members, Elevance is vulnerable to state rate lag, CMS Star Rating adjustments, and regulatory audits ($935M historical risk adjustment accrual in 2026). Furthermore, national competitors UNH and CI aggressively contest jumbo employer accounts, capping excess returns.

Elevance Health Inc. (ELV) trades at 13.7x forward earnings against a peer median of 14.4x. Its EV/EBITDA of 10.6x compares with a peer median of 11.3x. The comparison uses 4 peers: The Cigna Group, CVS Health Corporation, Humana Inc. and UnitedHealth Group Incorporated, as of 2026-10-22.

Elevance Health is rated Hold with Fair value of $474.64, offering 9.3% implied upside from $434.13 (as of 2026-10-21).

While third-quarter results demonstrated robust operational execution—prompting management to raise full-year earnings guidance and target double-digit earnings growth for FY2027 —the implied upside of 9.3% does not provide sufficient margin of safety to initiate fresh positions. Investors should maintain existing holdings and await further evidence of Medicaid margin normalization.